Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing Phase 1/2 study (SITC 2026) - Oct 2, 2026 - Abstract #611; Pres time: Nov 6, 2026; 10:00 AM - 07:00 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available
Checkpoint inhibition • P1/2 data • Melanoma • Oncology • Solid Tumor • IL2
|
|
Meredith McKean; Andrew Haydon; Sophia Frentzas; Siwen Hu-Lieskovan; Paul de Souza; John Powderly; Drew Rasco; Andrew Weickhardt; Ganessan Kichenadasse; Vinod Ganju; Nehal Lakhani; Jose Lutzky; Jeffrey Yorio; Eric Lander; Timothy Wyant; Jenny Tang; Lori Richards; Aron Knickerbocker; Yanay Ofran; James Vasselli
|